Ovr115 antibody compositions and methods of use
The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.
1. An isolated Ovr115 antibody wherein the antibody is produced by a hybridoma selected from the group consisting of American Type Culture Collection accession number PTA-5202, PTA-5916, PTA-5917, PTA-5918, PTA-5919, PTA-5920 and PTA-6550.
2. The isolated Ovr115 antibody of claim 1 , wherein said antibody binds to Ovr115 on a mammalian cell in vivo.
3. The antibody of claim 2 which internalizes upon binding to Ovr115 on a mammalian cell in vivo.
4. The antibody of claim 1 which is a monoclonal, a chimeric, a human or a humanized antibody.
5. The antibody of claim 1 which is conjugated to a growth inhibitory agent or a cytotoxic agent.
6. The antibody of claim 5 wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.
7. The antibody of claim 6 , wherein the toxin is selected from the group consisting of ricin, saponin, maytansinoid and calicheamicin.
8. The antibody of claim 1 , wherein said antibody inhibits the growth of Ovr115-expressing cancer cells.
9. The antibody of claim 8 which is a monoclonal, chimeric, humanized or human antibody.
10. The antibody of claim 9 which is produced in bacteria.
11. The antibody of claim 8 , wherein the cancer cells are from a cancer selected from the group consisting of ovarian, pancreatic and colon cancer.
12. The antibody of claim 1 which internalizes upon binding to Ovr115 on a mammalian cell in vivo.
13. The antibody of claim 1 which is produced by a hybridoma of American Type Culture Collection accession number PTA-6550.
14. The antibody of claim 1 which is produced by a hybridoma of American Type Culture Collection accession number PTA-5202.
15. The antibody of claim 1 which is produced by a hybridoma of American Type Culture Collection accession number PTA-5916.
16. The antibody of claim 1 which is produced by a hybridoma of American Type Culture Collection accession number PTA-5917.
17. The antibody of claim 1 which is produced by a hybridoma of American Type Culture Collection accession number PTA-5918.
18. The antibody of claim 1 which is produced by a hybridoma of American Type Culture Collection accession number PTA-5919.
19. The antibody of claim 1 which is produced by a hybridoma of American Type Culture Collection accession number PTA-5920.
20. The antibody of claim 1 , wherein said antibody is labeled.
21. The antibody of claim 20 wherein the label is selected from the group consisting of radio, fluorescent, gold particle, enzymatic and biotin labels.
22. The antibody of claim 1 , wherein said antibody inhibits Ovr115 protease activity.
23. A cell that produces the antibody of claim 1 .
24. A composition comprising the antibody of claim 1 , and a carrier.
25. The composition of claim 24 , wherein the antibody is conjugated to a cytotoxic agent.
26. The composition of claim 24 , wherein the antibody is a monoclonal, chimeric, human or humanized antibody and the carrier is a pharmaceutical carrier.
27. An article of manufacture comprising a container and the antibody of claim 1 .
28. The article of manufacture of claim 27 which further comprises a carrier.
29. The article of manufacture of claim 27 which further comprises a label or package insert.
30. A kit comprising a container and a composition comprising the antibody of claim 1 .
31. The kit of claim 30 wherein the antibody is coupled to a solid support.
32. The kit of claim 30 which further comprises a label or package insert.
33. A method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with the antibody of claim 2 , thereby killing the cancer cell.
34. The method of claim 33 , wherein the cancer cell is selected from the group consisting of ovarian, pancreatic and colon cancer cell.
35. The method of claim 33 , wherein the antibody is conjugated to a cytotoxic agent.
36. The method of claim 35 , wherein the cytotoxic agent is a toxin selected from the group consisting of maytansinoid, ricin, saporin and calicheamicin or a radioisotope.
37. The method of claim 33 , wherein the antibody is administered in conjunction with at least one chemotherapeutic agent.
38. The method of claim 37 wherein the chemotherapeutic agent is paclitaxel or derivatives thereof.
39. A method for determining if cells in a sample express Ovr115 comprising
(a) contacting a sample of cells with an Ovr115 antibody of claim 2 under conditions suitable for specific binding of the Ovr115 antibody to Ovr115 and
(b) determining the level of binding of the antibody to cells in the sample, or the level of Ovr115 antibody internalization by cells in said sample,
wherein Ovr115 antibody binding to cells in the sample or internalization of the Ovr115 antibody by cells in the sample indicate cells in the sample express Ovr115.
40. A method for detecting Ovr115 overexpression in a subject in need thereof comprising,
(a) combining a serum sample of a subject with an Ovr115 antibody of claim 2 under conditions suitable for specific binding of the Ovr115 antibody to Ovr115 in said serum sample
(b) determining the level of Ovr115 in the serum sample,
(c) comparing the level of Ovr115 determined in step b to the level of Ovr115 in a control,
wherein an increase in the level of Ovr115 in the serum sample from the subject as compared to the control is indicative of Ovr115 overexpression in the subject.
41. The method of claim 40 wherein the subject has cancer.
42. The method of claim 41 wherein the subject has ovarian, pancreatic or colon cancer.
43. A method for determining if cells in a sample express Ovr115 comprising
(a) contacting a sample of cells with an Ovr115 antibody of claim 1 under conditions suitable for specific binding of the Ovr115 antibody to Ovr115 and
(b) determining the level of binding of the antibody to cells in the sample, or the level of Ovr115 antibody internalization by cells in said sample,
wherein Ovr115 antibody binding to cells in the sample or internalization of the Ovr115 antibody by cells in the sample indicate cells in the sample express Ovr115.
44. A method for detecting Ovr115 overexpression in a subject in need thereof comprising,
(a) combining a serum sample of a subject with an Ovr115 antibody of claim 1 under conditions suitable for specific binding of the Ovr115 antibody to Ovr115 in said serum sample
(b) determining the level of Ovr115 in the serum sample,
(c) comparing the level of Ovr115 determined in step b to the level of Ovr115 in a control,
wherein an increase in the level of Ovr115 in the serum sample from the subject as compared to the control is indicative of Ovr115 overexpression in the subject.
45. The method of claim 44 wherein the subject has cancer.
46. The method of claim 44 wherein the subject has ovarian, pancreatic or colon cancer.